RECRUITING

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Description

This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.

Conditions

Prostate Cancer
Talk to us

Related Conditions:

Prostate Cancer

Study Overview

On this page

Study Details

Study overview

This study seeks to determine the clinical impact of Gene Expression Classifier (GEC) testing in prostate cancer care while also developing a pragmatic approach for improved GEC clinical use and future study.

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States, 48109

Detroit

Henry Ford Health System, Detroit, Michigan, United States, 48202

Detroit

Sherwood Medical Center, Detroit, Michigan, United States, 48221

Grand Rapids

Spectrum Health Medical Group, Grand Rapids, Michigan, United States, 49503

Holland

Western Michigan Urological Associates, Holland, Michigan, United States, 49423

Bronx

Montefiore Medical Center, Bronx, New York, United States, 10461

Chapel Hill

University of North Carolina, Chapel Hill, North Carolina, United States, 27599

Philadelphia

University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.
  • * Prostate biopsy tumor tissue (FFPR block) available for processing
  • * Age 18 years or older
  • * PSA \<20 ng/ml
  • * Grade Group (GG) 1 cancer with \> 2 biopsy cores involved with cancer OR GG2 cancer
  • * Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.
  • * Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease
  • * Nodal or metastatic prostate cancer (if staging imaging performed)
  • * Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.
  • * Prior prostate gene expression classier testing

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan Rogel Cancer Center,

Todd Morgan, M.D., PRINCIPAL_INVESTIGATOR, University of Michigan

Daniel Spratt, M.D., PRINCIPAL_INVESTIGATOR, University of Michigan

Study Record Dates

2025-07